Diabetes, also known as Diabetes mellitus is a condition, wherein the concentration of glucose increases in the blood due to shortage of insulin or insulin resistance. Some of the commonly experienced symptoms of diabetes include increased thirst, frequent urination, and increased appetite. Diabetes can be classified into two major types: Type 1 Diabetes and Type 2 Diabetes. Type 1 diabetes, also known as insulin-dependent diabetes is a chronic condition, wherein the body’s immune system destroys insulin producing cells or beta cells of the pancreas. Insulin is required in the body to help in absorption of glucose from the blood into body’s cell for energy. Type 2 diabetes also known as non-insulin dependent diabetes is a chronic condition, wherein the body is unable to use insulin in spite of having sufficient quantity of insulin in the body. Patients suffering from diabetes need to administer insulin externally, in order to maintain their blood glucose levels. Various types of insulin available in the market include rapid acting, short-acting, intermediate-acting, long-acting, ultralong-acting, and mixtures.
Market Dynamics
The increasing incidence of diabetes, rising research and development activities for the treatment of diabetes, and growing diabetes care health expenditure are the major factors that are expected to drive growth of the Latin America insulin vials market over the forecast period. Moreover, increasing adoption of inorganic growth strategies such as partnership, acquisitions, collaborations, and others by key players operating in the market is expected to further fuel growth of the market over the forecast period.
For instance, according to the Pan American Journal of Public Health, the number of people living with type 1 diabetes in the Americas is expected to increase from 35 million in 2000 to 64 million in 2025, out of which Latin America and Caribbean region would account for 62% or 40 million people in 2025.
Key features of the study:
- This report provides in-depth analysis of the Latin America insulin vials market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the Latin America insulin vials market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include Sanofi S.A, Novo Nordisk A/S, and Eli Lilly and Company
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The Latin America insulin vials market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Latin America insulin vials market
Detailed Segmentation:
- Latin America Insulin Vials Market, By Type of Insulin:
- Rapid Acting
- Short-acting
- Intermediate-acting
- Long-acting
- Ultralong-acting
- Mixtures
- Latin America Insulin Vials Market, By Indication:
- Type 1 Diabetes
- Type 2 Diabetes
- Latin America Insulin Vials Market, By Concentration:
- 100 units/ml
- 300 units/ml
- Others (Others include 200 units/ml and 500 units/ml)
- Latin America Insulin Vials Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Latin America Insulin Vials Market, By Country:
- Brazil
- By Type of Insulin
- Rapid Acting
- Short-acting
- Intermediate-acting
- Long-acting
- Ultralong-acting
- Mixtures
- By Indication
- Type 1 Diabetes
- Type 2 Diabetes
- By Concentration
- 100 units/ml
- 300 units/ml
- Others (Others include 200 units/ml and 500 units/ml)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Mexico
- By Type of Insulin
- Rapid Acting
- Short-acting
- Intermediate-acting
- Long-acting
- Ultralong-acting
- Mixtures
- By Indication
- Type 1 Diabetes
- Type 2 Diabetes
- By Concentration
- 100 units/ml
- 300 units/ml
- Others (Others include 200 units/ml and 500 units/ml)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Argentina
- By Type of Insulin
- Rapid Acting
- Short-acting
- Intermediate-acting
- Long-acting
- Ultralong-acting
- Mixtures
- By Indication
- Type 1 Diabetes
- Type 2 Diabetes
- By Concentration
- 100 units/ml
- 300 units/ml
- Others (Others include 200 units/ml and 500 units/ml)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Colombia
- By Type of Insulin
- Rapid Acting
- Short-acting
- Intermediate-acting
- Long-acting
- Ultralong-acting
- Mixtures
- By Indication
- Type 1 Diabetes
- Type 2 Diabetes
- By Concentration
- 100 units/ml
- 300 units/ml
- Others (Others include 200 units/ml and 500 units/ml)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Peru
- By Type of Insulin
- Rapid Acting
- Short-acting
- Intermediate-acting
- Long-acting
- Ultralong-acting
- Mixtures
- By Indication
- Type 1 Diabetes
- Type 2 Diabetes
- By Concentration
- 100 units/ml
- 300 units/ml
- Others (Others include 200 units/ml and 500 units/ml)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Venezuela
- By Type of Insulin
- Rapid Acting
- Short-acting
- Intermediate-acting
- Long-acting
- Ultralong-acting
- Mixtures
- By Indication
- Type 1 Diabetes
- Type 2 Diabetes
- By Concentration
- 100 units/ml
- 300 units/ml
- Others (Others include 200 units/ml and 500 units/ml)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Chile
- By Type of Insulin
- Rapid Acting
- Short-acting
- Intermediate-acting
- Long-acting
- Ultralong-acting
- Mixtures
- By Indication
- Type 1 Diabetes
- Type 2 Diabetes
- By Concentration
- 100 units/ml
- 300 units/ml
- Others (Others include 200 units/ml and 500 units/ml)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Ecuador
- By Type of Insulin
- Rapid Acting
- Short-acting
- Intermediate-acting
- Long-acting
- Ultralong-acting
- Mixtures
- By Indication
- Type 1 Diabetes
- Type 2 Diabetes
- By Concentration
- 100 units/ml
- 300 units/ml
- Others (Others include 200 units/ml and 500 units/ml)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Rest of Latin America
- By Type of Insulin
- Rapid Acting
- Short-acting
- Intermediate-acting
- Long-acting
- Ultralong-acting
- Mixtures
- By Indication
- Type 1 Diabetes
- Type 2 Diabetes
- By Concentration
- 100 units/ml
- 300 units/ml
- Others (Others include 200 units/ml and 500 units/ml)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Company Profiles
- Sanofi S.A*
- Company Overview
- Material Portfolio
- Financial Performance
- Key Highlights
- Market Strategies
- Novo Nordisk A/S
- Eli Lilly and Company
“*” marked represents similar segmentation in other categories in the respective section.
